If you were unable to attend our recent webinar, the recording is now available to watch on the CINP website and YouTube channel.

"Psilocybin in Depression: Insights From Contemporary Clinical Trials" features Dr. Joshua D. Rosenblat and Dr. Danica Johnson (University of Toronto & University Health Network, Canada), who provide a comprehensive overview of the latest clinical trial evidence on psilocybin for depression.

The webinar explores current findings on efficacy and safety, the regulatory and ethical frameworks underpinning clinical research, and the emerging challenges and opportunities that continue to shape this field.

Watch the recording at your convenience and stay up to date with developments in neuropsychopharmacology.

Watch Now

In June, CINP was proud to be represented at the African College of Neuropsychopharmacology (AfCNP) School on Precision Neuropsychopharmacology and Brain Health, held at the Aga Khan University Centre in Nairobi, Kenya.

Prof. Joseph Zohar, Chair of the CINP Education Committee, delivered the Dan Stein Memorial Lecture, entitled NbN and Precision in the Treatment of Psychiatric Disorders, sharing insights into precision approaches that continue to shape the future of neuropsychopharmacology.

The AfCNP School brought together clinicians, researchers, and early career professionals for an outstanding programme dedicated to scientific exchange, education, and collaboration. Events such as these play a vital role in strengthening international partnerships and advancing better brain and mental health care across the globe.

We thank our colleagues at AfCNP for their warm hospitality and for organizing such an inspiring educational initiative. CINP looks forward to continuing our collaboration in support of excellence in science, education, and patient care worldwide.

We're delighted to share that the International Journal of Neuropsychopharmacology has achieved an increased Impact Factor in the latest Journal Citation Reports release.

This growth reflects more than citations alone: readership, article usage, and engagement across the neuropsychopharmacology community demonstrate that research published in IJNP is being discovered, read, and used by scientists around the world.

We are particularly proud that our Impact Factor remains very close to the metric calculated without journal self-citations, highlighting that IJNP's influence is driven by the broader research community and reflecting genuine reach, relevance, and scientific impact. We extend our congratulations to the past editorial board team for this achievement.

Consider IJNP as the home for your next paper, and explore our Special Collections for opportunities to contribute to focused, high-impact areas of research.

Visit IJNP Website